KeyBanc Believes Healthequity (HQY) Won’t Stop Here


KeyBanc analyst Donald Hooker maintained a Buy rating on Healthequity (NASDAQ: HQY) today and set a price target of $105. The company’s shares closed on Friday at $94.21, close to its 52-week high of $94.57.

According to TipRanks.com, Hooker is a 5-star analyst with an average return of 16.9% and a 76.8% success rate. Hooker covers the Services sector, focusing on stocks such as Quest Diagnostics Inc, PRA Health Sciences, and Charles River Labs.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Healthequity with a $82.14 average price target, implying a -12.8% downside from current levels. In a report issued on August 30, Barrington also reiterated a Buy rating on the stock with a $85 price target.

.

See today’s analyst top recommended stocks >>

Healthequity’s market cap is currently $5.82B and has a P/E ratio of 105.85. The company has a Price to Book ratio of 14.66.

Based on the recent corporate insider activity of 84 insiders, corporate insider sentiment is negative on the stock. Most recently, in July 2018, Frank Medici, a Director at HQY sold 6,904 shares for a total of $555,013.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

HealthEquity, Inc. engages in the provision of healthcare saving solutions. Its products include healthcare saving and spending platform, health savings accounts, investment advisory services, reimbursement arrangements, and healthcare incentives. The company was founded by Stephen D. Neeleman on September 18, 2002 and is headquartered in Draper, UT.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts